Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2015, Article ID 835985, 19 pages
http://dx.doi.org/10.1155/2015/835985
Review Article

PPARs: Protectors or Opponents of Myocardial Function?

Temple University School of Medicine, Department of Pharmacology, Center for Translational Medicine, Philadelphia, PA 19140, USA

Received 31 July 2015; Revised 5 November 2015; Accepted 8 November 2015

Academic Editor: Nanping Wang

Copyright © 2015 Christine J. Pol et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Mozaffarian, E. J. Benjamin, A. S. Go et al., “Heart disease and stroke statistics—2015 update: a report from the American Heart Association,” Circulation, vol. 131, no. 4, pp. e29–e322, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Chandra, P. Huang, Y. Hamuro et al., “Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA,” Nature, vol. 456, no. 7220, pp. 350–356, 2008. View at Publisher · View at Google Scholar
  3. D. Auboeuf, J. Rieusset, L. Fajas et al., “Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients,” Diabetes, vol. 46, no. 8, pp. 1319–1327, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Varga, Z. Czimmerer, and L. Nagy, “PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1812, no. 8, pp. 1007–1022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. H. E. Xu, M. H. Lambert, V. G. Montana et al., “Molecular recognition of fatty acids by peroxisome proliferator-activated receptors,” Molecular Cell, vol. 3, no. 3, pp. 397–403, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. L. L. C. Poulsen, M. Siersbæk, and S. Mandrup, “PPARs: fatty acid sensors controlling metabolism,” Seminars in Cell and Developmental Biology, vol. 23, no. 6, pp. 631–639, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Feingold, M. S. Kim, J. Shigenaga, A. Moser, and C. Grunfeld, “Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response,” American Journal of Physiology—Endocrinology and Metabolism, vol. 286, no. 2, pp. E201–E207, 2004. View at Google Scholar · View at Scopus
  8. U. Maitra, S. Chang, N. Singh, and L. Li, “Molecular mechanism underlying the suppression of lipid oxidation during endotoxemia,” Molecular Immunology, vol. 47, no. 2-3, pp. 420–425, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Drosatos, Z. Drosatos-Tampakaki, R. Khan et al., “Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor α expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction,” The Journal of Biological Chemistry, vol. 286, no. 42, pp. 36331–36339, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Karbowska, Z. Kochan, and R. T. Smolenski, “Peroxisome proliferator-activated receptor α is downregulated in the failing human heart,” Cellular and Molecular Biology Letters, vol. 8, no. 1, pp. 49–53, 2003. View at Google Scholar · View at Scopus
  11. K. Masamura, N. Tanaka, M. Yoshida et al., “Myocardial metabolic regulation through peroxisome proliferator-activated receptor alpha after myocardial infarction,” Experimental and Clinical Cardiology, vol. 8, no. 2, pp. 61–66, 2003. View at Google Scholar · View at Scopus
  12. S. Narravula and S. P. Colgan, “Hypoxia-inducible factor 1-mediated inhibition of peroxisome proliferator-activated receptor alpha expression during hypoxia,” The Journal of Immunology, vol. 166, pp. 7543–7548, 2001. View at Google Scholar
  13. P. Razeghi, M. E. Young, S. Abbasi, and H. Taegtmeyer, “Hypoxia in vivo decreases peroxisome proliferator-activated receptor α-regulated gene expression in rat heart,” Biochemical and Biophysical Research Communications, vol. 287, no. 1, pp. 5–10, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. J. H. Parmentier, H. Schohn, M. Bronner et al., “Regulation of CYP4A1 and peroxisome proliferator-activated receptor alpha expression by interleukin-1β, interleukin-6, and dexamethasone in cultured fetal rat hepatocytes,” Biochemical Pharmacology, vol. 54, no. 8, pp. 889–898, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Chu, Y. Lin, M. S. Rao, and J. K. Reddy, “Cloning and identification of rat deoxyuridine triphosphatase as an inhibitor of peroxisome proliferator-activated receptor α,” The Journal of Biological Chemistry, vol. 271, no. 44, pp. 27670–27676, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Shi, M. Hon, and R. M. Evans, “The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 5, pp. 2613–2618, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. À. Cabrero, M. Alegret, R. M. Sánchez, T. Adzet, J. C. Laguna, and M. V. Carrera, “Increased reactive oxygen species production down-regulates peroxisome proliferator-activated α pathway in C2C12 skeletal muscle cells,” The Journal of Biological Chemistry, vol. 277, no. 12, pp. 10100–10107, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Roduit, J. Morin, F. Masse et al., “Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-α gene in the pancreatic β-cell,” The Journal of Biological Chemistry, vol. 275, no. 46, pp. 35799–35806, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Joly, R. Roduit, M.-L. Peyot et al., “Glucose represses PPARα gene expression via AMP-activated protein kinase but not via p38 mitogen-activated protein kinase in the pancreatic β-cell,” Journal of Diabetes, vol. 1, no. 4, pp. 263–272, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Panadero, H. Vidal, E. Herrera, and C. Bocos, “Nutritionally induced changes in the peroxisome proliferator-activated receptor-α gene expression in liver of suckling rats are dependent on insulinaemia,” Archives of Biochemistry and Biophysics, vol. 394, no. 2, pp. 182–188, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. S. A. Cook, T. Matsui, N. Li, and A. Rosenzweig, “Transcriptional effects of chronic akt activation in the heart,” Journal of Biological Chemistry, vol. 277, no. 25, pp. 22528–22533, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Riu, T. Ferre, A. Mas, A. Hidalgo, S. Franckhauser, and F. Bosch, “Overexpression of c-myc in diabetic mice restores altered expression of the transcription factor genes that regulate liver metabolism,” Biochemical Journal, vol. 368, no. 3, pp. 931–937, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. Y.-C. Zhou and D. J. Waxman, “STAT5b down-regulates peroxisome proliferator-activated receptor α transcription by inhibition of ligand-independent activation function region-1 trans-activation domain,” The Journal of Biological Chemistry, vol. 274, no. 42, pp. 29874–29882, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Carlsson, D. Lindén, M. Jalouli, and J. Oscarsson, “Effects of fatty acids and growth hormone on liver fatty acid binding protein and PPARα in rat liver,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 281, no. 4, pp. E772–E781, 2001. View at Google Scholar · View at Scopus
  25. G. P. Collett, A. M. Betts, M. I. Johnson et al., “Peroxisome proliferator-activated receptor α is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma,” Clinical Cancer Research, vol. 6, no. 8, pp. 3241–3248, 2000. View at Google Scholar · View at Scopus
  26. D. M. Tham, B. Martin-McNulty, Y.-X. Wang et al., “Angiotensin ii is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs,” Physiological Genomics, vol. 11, pp. 21–30, 2003. View at Google Scholar · View at Scopus
  27. T. Lemberger, B. Staels, R. Saladin, B. Desvergne, J. Auwerx, and W. Wahli, “Regulation of the peroxisome proliferator-activated receptor α gene by glucocorticoids,” The Journal of Biological Chemistry, vol. 269, no. 40, pp. 24527–24530, 1994. View at Google Scholar · View at Scopus
  28. I. P. Torra, T. Claudel, C. Duval, V. Kosykh, J.-C. Fruchart, and B. Staels, “Bile acids induce the expression of the human peroxisome proliferator-activated receptor α gene via activation of the farnesoid X receptor,” Molecular Endocrinology, vol. 17, no. 2, pp. 259–272, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. W. J. Lee, M. Kim, H.-S. Park et al., “AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARα and PGC-1,” Biochemical and Biophysical Research Communications, vol. 340, no. 1, pp. 291–295, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. R.-S. Meng, Z.-H. Pei, R. Yin et al., “Adenosine monophosphate-activated protein kinase inhibits cardiac hypertrophy through reactivating peroxisome proliferator-activated receptor-α signaling pathway,” European Journal of Pharmacology, vol. 620, no. 1–3, pp. 63–70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Ravnskjaer, M. Boergesen, L. T. Dalgaard, and S. Mandrup, “Glucose-induced repression of PPARα gene expression in pancreatic β-cells involves PP2A activation and AMPK inactivation,” Journal of Molecular Endocrinology, vol. 36, no. 2, pp. 289–299, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. J. M. Huss, I. P. Torra, B. Staels, V. Giguère, and D. P. Kelly, “Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle,” Molecular and Cellular Biology, vol. 24, no. 20, pp. 9079–9091, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Valmaseda, M. C. Carmona, M. J. Barberá et al., “Opposite regulation of PPAR-α and -β gene expression by both their ligands and retinoic acid in brown adipocytes,” Molecular and Cellular Endocrinology, vol. 154, no. 1-2, pp. 101–109, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. A. P. Beigneux, A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold, “The acute phase response is associated with retinoid X receptor repression in rodent liver,” Journal of Biological Chemistry, vol. 275, no. 21, pp. 16390–16399, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. N.-S. Yaacob, M.-N. Norazmi, G. G. Gibson, and G. E. N. Kass, “The transcription of the peroxisome proliferator-activated receptor α gene is regulated by protein kinase C,” Toxicology Letters, vol. 125, no. 1–3, pp. 133–141, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Iemitsu, T. Miyauchi, S. Maeda et al., “Aging-induced decrease in the PPAR-α level in hearts is improved by exercise training,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 283, no. 5, pp. H1750–H1760, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Vallanat, S. P. Anderson, H. M. Brown-Borg et al., “Analysis of the heat shock response in mouse liver reveals transcriptional dependence on the nuclear receptor peroxisome proliferator-activated receptor α (PPARα),” BMC Genomics, vol. 11, article 16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. S. L. Clarke, C. E. Robinson, and J. M. Gimble, “Caat/enhancer binding proteins directly modulate transcription from the peroxisome proliferator-activated receptor gamma 2 promoter,” Biochemical and Biophysical Research Communications, vol. 240, no. 1, pp. 99–103, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. Z. Wu, E. D. Rosen, R. Brun et al., “Cross-regulation of C/EBPα and PPARγ controls the transcriptional pathway of adipogenesis and insulin sensitivity,” Molecular Cell, vol. 3, no. 2, pp. 151–158, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. X. Wang and M. W. Kilgore, “Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells,” Molecular and Cellular Endocrinology, vol. 194, no. 1-2, pp. 123–133, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Prusty, B.-H. Park, K. E. Davis, and S. R. Farmer, “Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor γ (PPARγ) and C/EBPα gene expression during the differentiation of 3T3-L1 preadipocytes,” Journal of Biological Chemistry, vol. 277, no. 48, pp. 46226–46232, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Xiao, S. E. LeBlanc, Q. Wu et al., “Chromatin accessibility and transcription factor binding at the PPARγ2 promoter during adipogenesis is protein kinase a-dependent,” Journal of Cellular Physiology, vol. 226, no. 1, pp. 86–93, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. U. Kintscher, S. Wakino, D. Bruemmer et al., “TGF-β1 induces peroxisome proliferator-activated receptor γ1 and γ2 expression in human THP-1 monocytes,” Biochemical and Biophysical Research Communications, vol. 297, no. 4, pp. 794–799, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Hata, R. Nishimura, F. Ikeda et al., “Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis,” Molecular Biology of the Cell, vol. 14, no. 2, pp. 545–555, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Fu, J. Zhang, Y. Lin et al., “Early stimulation and late inhibition of peroxisome proliferator-activated receptor γ (ppar γ) gene expression by transforming growth factor β in human aortic smooth muscle cells: role of early growth-response factor-1 (egr-1), activator protein 1 (ap1) and smads,” Biochemical Journal, vol. 370, pp. 1019–1025, 2003. View at Google Scholar
  46. C. Chambrier, J.-P. Bastard, J. Rieusset et al., “Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma,” Obesity Research, vol. 10, no. 6, pp. 518–525, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. R. T. Oster, J. M. Tishinsky, Z. Yuan, and L. E. Robinson, “Docosahexaenoic acid increases cellular adiponectin mrna and secreted adiponectin protein, as well as ppargamma mrna, in 3t3-l1 adipocytes,” Applied Physiology, Nutrition, and Metabolism, vol. 35, pp. 783–789, 2010. View at Google Scholar
  48. H. Sundvold and S. Lien, “Identification of a novel peroxisome proliferator-activated receptor (PPAR) γ promoter in man and transactivation by the nuclear receptor RORα1,” Biochemical and Biophysical Research Communications, vol. 287, no. 2, pp. 383–390, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. R. K. Gupta, Z. Arany, P. Seale et al., “Transcriptional control of preadipocyte determination by Zfp423,” Nature, vol. 464, no. 7288, pp. 619–623, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. J.-F. Landrier, E. Gouranton, C. El Yazidi et al., “Adiponectin expression is induced by vitamin E via a peroxisome proliferator-activated receptor γ-dependent mechanism,” Endocrinology, vol. 150, no. 12, pp. 5318–5325, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. J. S. Welch, M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass, “PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6712–6717, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Jennewein, A. von Knethen, T. Schmid, and B. Brüne, “MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor γ (PPARγ) mRNA destabilization,” The Journal of Biological Chemistry, vol. 285, no. 16, pp. 11846–11853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Lee, J. Lee, E. Jung et al., “Ultraviolet a regulates adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells via up-regulation of Kruppel-like factor 2,” Journal of Biological Chemistry, vol. 285, no. 42, pp. 32647–32656, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. Q. Yang, C. Chen, S. Wu, Y. Zhang, X. Mao, and W. Wang, “Advanced glycation end products downregulates peroxisome proliferator-activated receptor γ expression in cultured rabbit chondrocyte through MAPK pathway,” European Journal of Pharmacology, vol. 649, no. 1–3, pp. 108–114, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Lee, E. Jung, J. Lee et al., “Anti-adipogenesis by 6-thioinosine is mediated by downregulation of PPAR γ through JNK-dependent upregulation of iNOS,” Cellular and Molecular Life Sciences, vol. 67, no. 3, pp. 467–481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Zhang, J. Berger, E. Hu et al., “Negative regulation of peroxisome proliferator-activated receptor-γ gene expression contributes to the antiadipogenic effects of tumor necrosis factor-α,” Molecular Endocrinology, vol. 10, no. 11, pp. 1457–1466, 1996. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Xing, J. P. Northrop, J. Russell Grove, K. E. Kilpatrick, S. U. Jui-Lan, and G. M. Ringold, “TNFα-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARγ without effects on Pref-1 expression,” Endocrinology, vol. 138, no. 7, pp. 2776–2783, 1997. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Meng, J. Zhou, H. Sasano, T. Suzuki, K. M. Zeitoun, and S. E. Bulun, “Tumor necrosis factor α and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein α and peroxisome proliferator-activated receptor γ: Mechanism of desmoplastic reaction,” Cancer Research, vol. 61, no. 5, pp. 2250–2255, 2001. View at Google Scholar · View at Scopus
  59. S. Kurebayashi, S. Sumitani, S. Kasayama, A. M. Jetten, and T. Hirose, “TNF-α inhibits 3T3-L1 adipocyte differentiation without downregulating the expression of C/EBPβ and δ,” Endocrine Journal, vol. 48, no. 2, pp. 249–253, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. S.-H. Park, H. J. Choi, H. Yang, K. H. Do, J. Kim, and Y. Moon, “Repression of peroxisome proliferator-activated receptor γ by mucosal ribotoxic insult-activated CCAAT/enhancer-binding protein homologous protein,” Journal of Immunology, vol. 185, no. 9, pp. 5522–5530, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. G. P. Lobo, J. Amengual, H. N. M. Li et al., “β,β-carotene decreases peroxisome proliferator receptor γ activity and reduces lipid storage capacity of adipocytes in a β,β-carotene oxygenase 1-dependent manner,” The Journal of Biological Chemistry, vol. 285, no. 36, pp. 27891–27899, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Xiao, N.-L. Wang, B. Sun, and G.-P. Cai, “Estrogen receptor mediates the effects of pseudoprotodiocsin on adipogenesis in 3t3-l1 cells,” American Journal of Physiology—Cell Physiology, vol. 299, no. 1, pp. C128–C138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. K. J. Waite, Z. E. Floyd, P. Arbour-Reily, and J. M. Stephens, “Interferon-γ-induced regulation of peroxisome proliferator-activated receptor gamma and stats in adipocytes,” The Journal of Biological Chemistry, vol. 276, no. 10, pp. 7062–7068, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Zhou, X. Jia, J. Qin et al., “Leptin inhibits PPARγ gene expression in hepatic stellate cells in the mouse model of liver damage,” Molecular and Cellular Endocrinology, vol. 323, no. 2, pp. 193–200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Escher, O. Braissant, S. Basu-Modak, L. Michalik, W. Wahli, and B. Desvergne, “Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding,” Endocrinology, vol. 142, no. 10, pp. 4195–4202, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. K. Kajita, T. Ishizuka, T. Mune et al., “Dehydroepiandrosterone down-regulates the expression of peroxisome proliferator-activated receptor γ in adipocytes,” Endocrinology, vol. 144, no. 1, pp. 253–259, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Oishi, I. Manabe, K. Tobe et al., “Krüppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation,” Cell Metabolism, vol. 1, no. 1, pp. 27–39, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Mori, H. Sakaue, H. Iguchi et al., “Role of krüppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis,” The Journal of Biological Chemistry, vol. 280, no. 13, pp. 12867–12875, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Sen Banerjee, M. W. Feinberg, M. Watanabe et al., “The Krüppel-like factor KLF2 inhibits peroxisome proliferator-activated receptor-γ expression and adipogenesis,” The Journal of Biological Chemistry, vol. 278, no. 4, pp. 2581–2584, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Kawamura, Y. Tanaka, R. Kawamori, and S. Maeda, “Overexpression of kruppel-like factor 7 regulates adipocytokine gene expressions in human adipocytes and inhibits glucose-induced insulin secretion in pancreatic beta-cell line,” Molecular Endocrinology, vol. 20, no. 4, pp. 844–856, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. D. Li, S. Yea, S. Li et al., “Krüppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1,” The Journal of Biological Chemistry, vol. 280, no. 29, pp. 26941–26952, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. W. Qi, X. Chen, J. Holian, C. Y. R. Tan, D. J. Kelly, and C. A. Pollock, “Transcription factors Krüppel-like factor 6 and peroxisome proliferator-activated receptor-γ mediate high glucose-induced thioredoxin-interacting protein,” American Journal of Pathology, vol. 175, no. 5, pp. 1858–1867, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. V. A. Narkar, M. Downes, R. T. Yu et al., “AMPK and PPARδ agonists are exercise mimetics,” Cell, vol. 134, no. 3, pp. 405–415, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. H. E. Broxmeyer and C. Mantel, “A ROSy future for metabolic regulation of HSC division,” Nature Medicine, vol. 18, no. 9, pp. 1334–1336, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. C.-H. Woo, M. P. Massett, T. Shishido et al., “ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor δ (PPARδ) stimulation,” The Journal of Biological Chemistry, vol. 281, no. 43, pp. 32164–32174, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. J. D. Brown, E. Oligino, D. J. Rader, A. Saghatelian, and J. Plutzky, “VLDL hydrolysis by hepatic lipase regulates PPARδ transcriptional responses,” PLoS ONE, vol. 6, no. 7, Article ID e21209, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. D. V. Chistyakov, S. Aleshin, M. G. Sergeeva, and G. Reiser, “Regulation of peroxisome proliferator-activated receptor β/δ expression and activity levels by toll-like receptor agonists and MAP kinase inhibitors in rat astrocytes,” Journal of Neurochemistry, vol. 130, no. 4, pp. 563–574, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Shrivastav, L. Zhang, K. Okamoto et al., “HIV-1 Vpr enhances PPARβ/δ-mediated transcription, increases PDK4 expression, and reduces PDC activity,” Molecular Endocrinology, vol. 27, no. 9, pp. 1564–1576, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. D. Holst, S. Luquet, V. Nogueira, K. Kristiansen, X. Leverve, and P. A. Grimaldi, “Nutritional regulation and role of peroxisome proliferator-activated receptor δ in fatty acid catabolism in skeletal muscle,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1633, no. 1, pp. 43–50, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. T. Haffar, F. A. Bérubé-Simard, and N. Bousette, “Cardiomyocyte lipotoxicity is mediated by Il-6 and causes down-regulation of PPARs,” Biochemical and Biophysical Research Communications, vol. 459, no. 1, pp. 54–59, 2015. View at Publisher · View at Google Scholar
  81. A. Planavila, J. C. Laguna, and M. Vázquez-Carrera, “Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-κB activation,” Biochimica et Biophysica Acta, vol. 1687, no. 1–3, pp. 76–83, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. G. Haemmerle, T. Moustafa, G. Woelkart et al., “ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1,” Nature Medicine, vol. 17, no. 9, pp. 1076–1085, 2011. View at Publisher · View at Google Scholar
  83. K. A. Burns and J. P. Vanden Heuvel, “Modulation of PPAR activity via phosphorylation,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 952–960, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. J. H. Choi, A. S. Banks, J. L. Estall et al., “Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5,” Nature, vol. 466, no. 7305, pp. 451–456, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. A. S. Banks, F. E. McAllister, J. P. G. Camporez et al., “An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ,” Nature, vol. 517, no. 7534, pp. 391–395, 2015. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Adams, M. J. Reginato, D. Shao, M. A. Lazar, and V. K. Chatterjee, “Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site,” Journal of Biological Chemistry, vol. 272, no. 8, pp. 5128–5132, 1997. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Shalev, C. A. Siegrist-Kaiser, P. M. Yen et al., “The peroxisome proliferator-activated receptor alpha is a phosphoprotein: regulation by insulin,” Endocrinology, vol. 137, no. 10, pp. 4499–4502, 1996. View at Publisher · View at Google Scholar · View at Scopus
  88. G. Lazennec, L. Canaple, D. Saugy, and W. Wahli, “Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators,” Molecular Endocrinology, vol. 14, no. 12, pp. 1962–1975, 2000. View at Publisher · View at Google Scholar · View at Scopus
  89. D. K. Krämer, L. Al-Khalili, S. Perrini et al., “Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator—activated receptor δ,” Diabetes, vol. 54, no. 4, pp. 1157–1163, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. J.-H. Kim, K. W. Park, E.-W. Lee et al., “Suppression of PPARγ through MKRN1-mediated ubiquitination and degradation prevents adipocyte differentiation,” Cell Death and Differentiation, vol. 21, no. 4, pp. 594–603, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. R. Diezko and G. Suske, “Ligand binding reduces sumoylation of the peroxisome proliferator-activated receptor γ (PPARγ) activation function 1 (AF1) domain,” PLoS ONE, vol. 8, no. 6, Article ID e66947, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. K. M. Wadosky and M. S. Willis, “The story so far: post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and sumoylation,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 302, no. 3, pp. H515–H526, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. D. Yamashita, T. Yamaguchi, M. Shimizu, N. Nakata, F. Hirose, and T. Osumi, “The transactivating function of peroxisome proliferator-activated receptor γ is negatively regulated by SUMO conjugation in the amino-terminal domain,” Genes to Cells, vol. 9, no. 11, pp. 1017–1029, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. B. Pourcet, I. Pineda-Torra, B. Derudas, B. Staels, and C. Glineur, “SUMOylation of human peroxisome proliferator-activated receptor α inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR,” The Journal of Biological Chemistry, vol. 285, no. 9, pp. 5983–5992, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. J. E. Rodriguez, J. Y. Liao, J. He et al., “The ubiquitin ligase MuRF1 regulates PPARα activity in the heart by enhancing nuclear export via monoubiquitination,” Molecular and Cellular Endocrinology, vol. 413, pp. 36–48, 2015. View at Publisher · View at Google Scholar
  96. G. A. Ngoh, H. T. Facundo, A. Zafir, and S. P. Jones, “O-GlcNAc signaling in the cardiovascular system,” Circulation Research, vol. 107, no. 2, pp. 171–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. S. Ji, S. Y. Park, J. Roth, H. S. Kim, and J. W. Cho, “O-GlcNAc modification of PPARγ reduces its transcriptional activity,” Biochemical and Biophysical Research Communications, vol. 417, no. 4, pp. 1158–1163, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. X. Yang, P. P. Ongusaha, P. D. Miles et al., “Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance,” Nature, vol. 451, no. 7181, pp. 964–969, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Choudhary, C. Kumar, F. Gnad et al., “Lysine acetylation targets protein complexes and co-regulates major cellular functions,” Science, vol. 325, no. 5942, pp. 834–840, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. X. Jiang, X. Ye, W. Guo, H. Lu, and Z. Gao, “Inhibition of HDAC3 promotes ligand-independent PPARγ activation by protein acetylation,” Journal of Molecular Endocrinology, vol. 53, no. 2, pp. 191–200, 2014. View at Publisher · View at Google Scholar · View at Scopus
  101. L. Fajas, V. Egler, R. Reiter et al., “The retinoblastoma-histone deacetylase 3 complex inhibits PPARγ and adipocyte differentiation,” Developmental Cell, vol. 3, no. 6, pp. 903–910, 2002. View at Publisher · View at Google Scholar · View at Scopus
  102. R. L. Montgomery, M. J. Potthoff, M. Haberland et al., “Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice,” The Journal of Clinical Investigation, vol. 118, no. 11, pp. 3588–3597, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli, “Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors,” Cell, vol. 68, no. 5, pp. 879–887, 1992. View at Publisher · View at Google Scholar · View at Scopus
  104. R. Lahey, X. Wang, A. N. Carley, and E. D. Lewandowski, “Dietary fat supply to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride,” Circulation, vol. 130, pp. 1790–1799, 2014. View at Publisher · View at Google Scholar · View at Scopus
  105. G. D. Lopaschuk, J. R. Ussher, C. D. L. Folmes, J. S. Jaswal, and W. C. Stanley, “Myocardial fatty acid metabolism in health and disease,” Physiological Reviews, vol. 90, no. 1, pp. 207–258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. T. C. Leone, C. J. Weinheimer, and D. P. Kelly, “A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 13, pp. 7473–7478, 1999. View at Publisher · View at Google Scholar · View at Scopus
  107. B. N. Finck, J. J. Lehman, T. C. Leone et al., “The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus,” Journal of Clinical Investigation, vol. 109, no. 1, pp. 121–130, 2002. View at Publisher · View at Google Scholar · View at Scopus
  108. N. H. Banke, A. R. Wende, T. C. Leone et al., “Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARα,” Circulation Research, vol. 107, no. 2, pp. 233–241, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. J. M. Brandt, F. Djouadi, and D. P. Kelly, “Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor α,” Journal of Biological Chemistry, vol. 273, no. 37, pp. 23786–23792, 1998. View at Publisher · View at Google Scholar · View at Scopus
  110. D. A. Prosdocimo, J. E. John, L. Zhang et al., “KLF15 and PPARα cooperate to regulate cardiomyocyte lipid gene expression and oxidation,” PPAR Research, vol. 2015, Article ID 201625, 10 pages, 2015. View at Publisher · View at Google Scholar
  111. A. Chawla, E. J. Schwarz, D. D. Dimaculangan, and M. A. Lazar, “Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation,” Endocrinology, vol. 135, no. 2, pp. 798–800, 1994. View at Publisher · View at Google Scholar · View at Scopus
  112. P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  113. N.-H. Son, T.-S. Park, H. Yamashita et al., “Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in mice,” The Journal of Clinical Investigation, vol. 117, no. 10, pp. 2791–2801, 2007. View at Publisher · View at Google Scholar · View at Scopus
  114. Y.-X. Wang, C.-H. Lee, S. Tiep et al., “Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003. View at Publisher · View at Google Scholar · View at Scopus
  115. L. Cheng, G. Ding, Q. Qin et al., “Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy,” Nature Medicine, vol. 10, no. 11, pp. 1245–1250, 2004. View at Publisher · View at Google Scholar · View at Scopus
  116. F. Djouadi, C. J. Weinheimer, J. E. Saffitz et al., “A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α-deficient mice,” The Journal of Clinical Investigation, vol. 102, no. 6, pp. 1083–1091, 1998. View at Publisher · View at Google Scholar · View at Scopus
  117. K. Watanabe, H. Fujii, T. Takahashi et al., “Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor α associated with age-dependent cardiac toxicity,” The Journal of Biological Chemistry, vol. 275, no. 29, pp. 22293–22299, 2000. View at Publisher · View at Google Scholar · View at Scopus
  118. F. M. Campbell, R. Kozak, A. Wagner et al., “A role for peroxisome proliferator-activated receptor alpha (pparα ) in the control of cardiac malonyl-coa levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking pparα are associated with higher concentrations of malonyl-coa and reduced expression of malonyl-coa decarboxylase,” The Journal of Biological Chemistry, vol. 277, no. 6, pp. 4098–4103, 2002. View at Publisher · View at Google Scholar
  119. J. Liu, P. Wang, L. He et al., “Cardiomyocyte-restricted deletion of PPARβ/δ in PPARα-null mice causes impaired mitochondrial biogenesis and defense, but no further depression of myocardial fatty acid oxidation,” PPAR Research, vol. 2011, Article ID 372854, 13 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. I. Luptak, J. A. Balschi, Y. Xing, T. C. Leone, D. P. Kelly, and R. Tian, “Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-α-null hearts can be rescued by increasing glucose transport and utilization,” Circulation, vol. 112, no. 15, pp. 2339–2346, 2005. View at Publisher · View at Google Scholar · View at Scopus
  121. C. Loichot, L. Jesel, A. Tesse et al., “Deletion of peroxisome proliferator-activated receptor-α induces an alteration of cardiac functions,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 291, no. 1, pp. H161–H166, 2006. View at Publisher · View at Google Scholar · View at Scopus
  122. A. Guellich, T. Damy, Y. Lecarpentier et al., “Role of oxidative stress in cardiac dysfunction of PPARα-/- mice,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 293, no. 1, pp. H93–H102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  123. A. Guellich, T. Damy, M. Conti et al., “Tempol prevents cardiac oxidative damage and left ventricular dysfunction in the PPAR-α KO mouse,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 304, no. 11, pp. H1505–H1512, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. S. Oka, R. Alcendor, P. Zhai et al., “PPARα-sirt1 complex mediates cardiac hypertrophy and failure through suppression of the err transcriptional pathway,” Cell Metabolism, vol. 14, no. 5, pp. 598–611, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. S.-I. Oka, P. Zhai, R. Alcendor, J. Y. Park, B. Tian, and J. Sadoshima, “Suppression of ERR targets by a PPARα/Sirt1 complex in the failing heart,” Cell Cycle, vol. 11, no. 5, pp. 856–864, 2012. View at Publisher · View at Google Scholar · View at Scopus
  126. Y. Barak, M. C. Nelson, E. S. Ong et al., “PPARγ is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999. View at Publisher · View at Google Scholar · View at Scopus
  127. S. Z. Duan, C. Y. Ivashchenko, M. W. Russell, D. S. Milstone, and R. M. Mortensen, “Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice,” Circulation Research, vol. 97, pp. 372–379, 2005. View at Google Scholar
  128. E. Caglayan, B. Stauber, A. R. Collins et al., “Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis,” Diabetes, vol. 57, no. 9, pp. 2470–2479, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. M. Barbieri, C. Di Filippo, A. Esposito et al., “Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice,” PLoS ONE, vol. 7, no. 4, Article ID e35999, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. S. Hinrichs, J. Heger, R. Schreckenberg et al., “Controlling cardiomyocyte length: the role of renin and PPAR-γ,” Cardiovascular Research, vol. 89, no. 2, pp. 344–352, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. G. Ding, M. Fu, Q. Qin et al., “Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage,” Cardiovascular Research, vol. 76, no. 2, pp. 269–279, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. J. Luo, S. Wu, J. Liu et al., “Conditional PPARγ knockout from cardiomyocytes of adult mice impairs myocardial fatty acid utilization and cardiac function,” American Journal of Translational Research, vol. 3, no. 1, pp. 61–72, 2011. View at Google Scholar · View at Scopus
  133. Y. Barak, D. Liao, W. He et al., “Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 303–308, 2002. View at Publisher · View at Google Scholar · View at Scopus
  134. J. M. Peters, S. S. T. Lee, W. Li et al., “Growths, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ),” Molecular and Cellular Biology, vol. 20, no. 14, pp. 5119–5128, 2000. View at Publisher · View at Google Scholar · View at Scopus
  135. P. Wang, J. Liu, Y. Li et al., “Peroxisome proliferator-activated receptor δ is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart,” Circulation Research, vol. 106, no. 5, pp. 911–919, 2010. View at Publisher · View at Google Scholar · View at Scopus
  136. E. M. Burkart, N. Sambandam, X. Han et al., “Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart,” The Journal of Clinical Investigation, vol. 117, no. 12, pp. 3930–3939, 2007. View at Publisher · View at Google Scholar · View at Scopus
  137. J. Liu, P. Wang, J. Luo et al., “Peroxisome proliferator-activated receptor β/δ activation in adult hearts facilitates mitochondrial function and cardiac performance under pressure-overload condition,” Hypertension, vol. 57, no. 2, pp. 223–230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  138. N.-H. Son, S. Yu, J. Tuinei et al., “PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation,” The Journal of Clinical Investigation, vol. 120, no. 10, pp. 3443–3454, 2010. View at Publisher · View at Google Scholar · View at Scopus
  139. E. Bedu, D. Desplanches, J. Pequignot, B. Bordier, and B. Desvergne, “Double gene deletion reveals the lack of cooperation between PPARα and PPARβ in skeletal muscle,” Biochemical and Biophysical Research Communications, vol. 357, no. 4, pp. 877–881, 2007. View at Publisher · View at Google Scholar · View at Scopus
  140. E. Strand, B. Bjorndal, O. Nygard et al., “Long-term treatment with the pan-PPAR agonist tetradecylthioacetic acid or fish oil is associated with increased cardiac content of n-3 fatty acids in rat,” Lipids in Health and Disease, vol. 11, article 82, 2012. View at Publisher · View at Google Scholar · View at Scopus
  141. A. D. Hafstad, A. M. Khalid, M. Hagve et al., “Cardiac peroxisome proliferator-activated receptor-α activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss,” Cardiovascular Research, vol. 83, no. 3, pp. 519–526, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. Z.-J. Wang, Q. Liu, P.-P. Li, C.-H. Zou, and Z.-F. Shen, “Effect of GCP-02, a PPARα/β dual activator, on glucose and lipid metabolism in insulin-resistant mice,” European Journal of Pharmacology, vol. 580, no. 1-2, pp. 277–283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  143. R. Hanf, L. J. Millatt, B. Cariou et al., “The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects,” Diabetes and Vascular Disease Research, vol. 11, no. 6, pp. 440–447, 2014. View at Publisher · View at Google Scholar · View at Scopus
  144. S. K. Engle, P. F. Solter, K. M. Credille et al., “Detection of left ventricular hypertrophy in rats administered a peroxisome proliferator-activated receptor α/γ dual agonist using natriuretic peptides and imaging,” Toxicological Sciences, vol. 114, no. 2, pp. 183–192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  145. M. E. Poynter and R. A. Daynes, “Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging,” The Journal of Biological Chemistry, vol. 273, no. 49, pp. 32833–32841, 1998. View at Publisher · View at Google Scholar · View at Scopus
  146. P. Howroyd, C. Swanson, C. Dunn, R. C. Cattley, and J. C. Corton, “Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor α (PPARα),” Toxicologic Pathology, vol. 32, no. 5, pp. 591–599, 2004. View at Publisher · View at Google Scholar · View at Scopus
  147. H. J. Atherton, M. K. Gulston, N. J. Bailey et al., “Metabolomics of the interaction between PPAR-α and age in the PPAR-α-null mouse,” Molecular Systems Biology, vol. 5, article 259, 2009. View at Publisher · View at Google Scholar · View at Scopus
  148. L. Han, M. Li, Y. Liu, C. Han, and P. Ye, “Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator-activated receptors in rats,” Pharmacology, vol. 89, no. 1-2, pp. 74–82, 2012. View at Publisher · View at Google Scholar · View at Scopus
  149. R. A. Daynes and D. C. Jones, “Emerging roles of PPARs in inflammation and immunity,” Nature Reviews Immunology, vol. 2, no. 10, pp. 748–759, 2002. View at Publisher · View at Google Scholar · View at Scopus
  150. J. Youssef and M. Badr, “Role of peroxisome proliferator-activated receptors in inflammation control,” Journal of Biomedicine and Biotechnology, vol. 2004, no. 3, pp. 156–166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  151. P. M. Barger, J. M. Brandt, T. C. Leone, C. J. Weinheimer, and D. P. Kelly, “Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth,” The Journal of Clinical Investigation, vol. 105, no. 12, pp. 1723–1730, 2000. View at Publisher · View at Google Scholar · View at Scopus
  152. M. E. Young, F. A. Laws, G. W. Goodwin, and H. Taegtmeyer, “Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart,” The Journal of Biological Chemistry, vol. 276, no. 48, pp. 44390–44395, 2001. View at Publisher · View at Google Scholar · View at Scopus
  153. M. E. Young, S. Patil, J. Ying et al., “Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor α in the adult rodent heart,” The FASEB Journal, vol. 15, no. 3, pp. 833–845, 2001. View at Publisher · View at Google Scholar · View at Scopus
  154. Z. Jia, R. Xue, G. Liu et al., “HMGB1 is involved in the protective effect of the PPARα agonist fenofibrate against cardiac hypertrophy,” PPAR Research, vol. 2014, Article ID 541394, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  155. J. Zou, K. Le, S. Xu et al., “Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4,” Molecular and Cellular Endocrinology, vol. 370, no. 1-2, pp. 103–112, 2013. View at Publisher · View at Google Scholar · View at Scopus
  156. T.-A. S. Duhaney, L. Cui, M. K. Rude et al., “Peroxisome proliferator-activated receptor α-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload,” Hypertension, vol. 49, no. 5, pp. 1084–1094, 2007. View at Publisher · View at Google Scholar · View at Scopus
  157. M. Rose, P. Balakumar, and M. Singh, “Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats,” Pharmacology, vol. 80, no. 2-3, pp. 177–184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  158. S. Purushothaman, M. M. Sathik, and R. R. Nair, “Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart,” Journal of Cardiovascular Pharmacology, vol. 58, no. 3, pp. 254–262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  159. P. J. H. Smeets, B. E. J. Teunissen, P. H. M. Willemsen et al., “Cardiac hypertrophy is enhanced in PPARα−/− mice in response to chronic pressure overload,” Cardiovascular Research, vol. 78, no. 1, pp. 79–89, 2008. View at Publisher · View at Google Scholar · View at Scopus
  160. P. J. H. Smeets, H. M. de Vogel-van Den Bosch, P. H. M. Willemsen et al., “Transcriptomic analysis of PPARα-dependent alterations during cardiac hypertrophy,” Physiological Genomics, vol. 36, no. 1, pp. 15–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  161. K.-U. Jarr, S. Eschricht, L. C. Burkly et al., “TNF-like weak inducer of apoptosis aggravates left ventricular dysfunction after myocardial infarction in mice,” Mediators of Inflammation, vol. 2014, Article ID 131950, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  162. P.-H. Lou, L. Zhang, E. Lucchinetti et al., “Infarct-remodelled hearts with limited oxidative capacity boost fatty acid oxidation after conditioning against ischaemia/reperfusion injury,” Cardiovascular Research, vol. 97, no. 2, pp. 251–261, 2013. View at Publisher · View at Google Scholar · View at Scopus
  163. E. E. Morgan, J. H. Rennison, M. E. Young et al., “Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 290, no. 5, pp. H1899–H1904, 2006. View at Publisher · View at Google Scholar · View at Scopus
  164. W. Linz, P. Wohlfart, M. Baader et al., “The peroxisome proliferator-activated receptor-α (PPAR-α) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats,” Acta Pharmacologica Sinica, vol. 30, no. 7, pp. 935–946, 2009. View at Publisher · View at Google Scholar · View at Scopus
  165. T. Ravingerová, S. Čarnická, M. Nemčeková et al., “PPAR-alpha activation as a preconditioning-like intervention in rats in vivo confers myocardial protection against acute ischaemia-reperfusion injury: involvement of PI3K-Akt,” Canadian Journal of Physiology and Pharmacology, vol. 90, no. 8, pp. 1135–1144, 2012. View at Publisher · View at Google Scholar · View at Scopus
  166. M. Nemcekova, S. Carnicka, M. Ferko, M. Murarikova, V. Ledvenyiova, and T. Ravingerova, “Treatment of rats with hypolipidemic compound pirinixic acid protects their hearts against ischemic injury: are mitochondrial K(ATP) channels and reactive oxygen species involved?” Physiological Research/Academia Scientiarum Bohemoslovaca, vol. 62, no. 5, pp. 577–584, 2013. View at Google Scholar
  167. E. Barlaka, V. Ledvényiová, E. Galatou et al., “Delayed cardioprotective effects of wy-14643 are associated with inhibition of mmp-2 and modulation of bcl-2 family proteins through PPAR-α activation in rat hearts subjected to global ischaemia-reperfusion1,” Canadian Journal of Physiology and Pharmacology, vol. 91, no. 8, pp. 608–616, 2013. View at Publisher · View at Google Scholar · View at Scopus
  168. T. Ravingerová, S. Čarnická, V. Ledvényiová et al., “Upregulation of genes involved in cardiac metabolism enhances myocardial resistance to ischemia/reperfusion in the rat heart,” Physiological Research, vol. 62, supplement 1, pp. S151–S163, 2013. View at Google Scholar · View at Scopus
  169. Q. Tian, F. A. Grzemski, S. Panagiotopoulos, and J. T. Ahokas, “Peroxisome proliferator-activated receptor alpha agonist, clofibrate, has profound influence on myocardial fatty acid composition,” Chemico-Biological Interactions, vol. 160, no. 3, pp. 241–251, 2006. View at Publisher · View at Google Scholar · View at Scopus
  170. G. Barreto-Torres, R. Parodi-Rullán, and S. Javadov, “The role of PPARα in metformin-induced attenuation of mitochondrial dysfunction in acute cardiac ischemia/reperfusion in rats,” International Journal of Molecular Sciences, vol. 13, no. 12, pp. 7694–7709, 2012. View at Publisher · View at Google Scholar
  171. N. S. Wayman, B. L. Ellis, and C. Thiemermann, “Ligands of the peroxisome proliferator-activated receptor-PPAR-α reduce myocardial infarct size,” Medical Science Monitor, vol. 8, no. 7, pp. BR243–BR247, 2002. View at Google Scholar
  172. A. A. Bulhak, P.-O. Sjöquist, C.-B. Xu, L. Edvinsson, and J. Pernow, “Protection against myocardial ischaemia/reperfusion injury by PPAR-α activation is related to production of nitric oxide and endothelin-1,” Basic Research in Cardiology, vol. 101, no. 3, pp. 244–252, 2006. View at Publisher · View at Google Scholar · View at Scopus
  173. N. S. Wayman, Y. Hattori, M. C. Mcdonald et al., “Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size,” The FASEB Journal, vol. 16, no. 9, pp. 1027–1040, 2002. View at Publisher · View at Google Scholar · View at Scopus
  174. H. El Azzouzi, S. Leptidis, M. Bourajjaj et al., “Peroxisome proliferator-activated receptor (PPAR) gene profiling uncovers insulin-like growth factor-1 as a PPARα target gene in cardioprotection,” The Journal of Biological Chemistry, vol. 286, no. 16, pp. 14598–14607, 2011. View at Publisher · View at Google Scholar · View at Scopus
  175. T.-L. Yue, W. Bao, B. M. Jucker et al., “Activation of peroxisome proliferator-activated receptor-α protects the heart from ischemia/reperfusion injury,” Circulation, vol. 108, no. 19, pp. 2393–2399, 2003. View at Publisher · View at Google Scholar · View at Scopus
  176. N. Sambandam, D. Morabito, C. Wagg, B. N. Finck, D. P. Kelly, and G. D. Lopaschuk, “Chronic activation of PPARα is detrimental to cardiac recovery after ischemia,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 290, no. 1, pp. H87–H95, 2006. View at Publisher · View at Google Scholar · View at Scopus
  177. O. Dewald, S. Sharma, J. Adrogue et al., “Downregulation of peroxisome proliferator-activated receptor-α gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity,” Circulation, vol. 112, no. 3, pp. 407–415, 2005. View at Publisher · View at Google Scholar · View at Scopus
  178. G. D. Duerr, J. C. Heinemann, V. Arnoldi et al., “Cardiomyocyte specific peroxisome proliferator-activated receptor-alpha overexpression leads to irreversible damage in ischemic murine heart,” Life Sciences, vol. 102, no. 2, pp. 88–97, 2014. View at Publisher · View at Google Scholar · View at Scopus
  179. R. J. Langley, E. L. Tsalik, J. C. van Velkinburgh et al., “An integrated clinico-metabolomic model improves prediction of death in sepsis,” Science Translational Medicine, vol. 5, no. 195, Article ID 195ra95, 2013. View at Publisher · View at Google Scholar
  180. J. Schilling, L. Lai, N. Sambandam, C. E. Dey, T. C. Leone, and D. P. Kelly, “Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor γ coactivator-1 signaling,” Circulation: Heart Failure, vol. 4, no. 4, pp. 474–482, 2011. View at Publisher · View at Google Scholar · View at Scopus
  181. K. Drosatos, Z. Drosatos-Tampakaki, R. Khan et al., “Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor α expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction,” Journal of Biological Chemistry, vol. 286, no. 42, pp. 36331–36339, 2011. View at Publisher · View at Google Scholar · View at Scopus
  182. K. Drosatos, R. S. Khan, C. M. Trent et al., “Peroxisome proliferator-activated receptor-γ activation prevents sepsis-related cardiac dysfunction and mortality in mice,” Circulation: Heart Failure, vol. 6, no. 3, pp. 550–562, 2013. View at Publisher · View at Google Scholar · View at Scopus
  183. M. Asakawa, H. Takano, T. Nagai et al., “Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo,” Circulation, vol. 105, no. 10, pp. 1240–1246, 2002. View at Publisher · View at Google Scholar · View at Scopus
  184. M. F. Kato, R. Shibata, K. Obata et al., “Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt,” Journal of Hypertension, vol. 26, no. 8, pp. 1669–1676, 2008. View at Publisher · View at Google Scholar · View at Scopus
  185. K. Gong, Y.-F. Chen, P. Li et al., “Transforming growth factor-β inhibits myocardial PPARγ expression in pressure overload-induced cardiac fibrosis and remodeling in mice,” Journal of Hypertension, vol. 29, no. 9, pp. 1810–1819, 2011. View at Publisher · View at Google Scholar · View at Scopus
  186. S. Zambrano, A. J. Blanca, M. V. Ruiz-Armenta et al., “L-carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression,” Biochemical Pharmacology, vol. 85, no. 7, pp. 937–944, 2013. View at Publisher · View at Google Scholar · View at Scopus
  187. C. A. Lygate, K. Hulbert, M. Monfared, M. A. Cole, K. Clarke, and S. Neubauer, “The PPARγ-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction,” Cardiovascular Research, vol. 58, no. 3, pp. 632–637, 2003. View at Publisher · View at Google Scholar · View at Scopus
  188. L. Tao, Y. Wang, E. Gao et al., “Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction,” Circulation Research, vol. 106, no. 2, pp. 409–417, 2010. View at Publisher · View at Google Scholar · View at Scopus
  189. Y. Maejima, H. Okada, G. Haraguchi et al., “Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma,” Laboratory Investigation, vol. 91, no. 6, pp. 932–944, 2011. View at Publisher · View at Google Scholar · View at Scopus
  190. T. Shiomi, H. Tsutsui, S. Hayashidani et al., “Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction,” Circulation, vol. 106, no. 24, pp. 3126–3132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  191. M. Abe, Y. Takiguchi, S. Ichimaru, S. Kaji, K. Tsuchiya, and K. Wada, “Different effect of acute treatment with rosiglitazone on rat myocardial ischemia/reperfusion injury by administration method,” European Journal of Pharmacology, vol. 589, no. 1–3, pp. 215–219, 2008. View at Publisher · View at Google Scholar · View at Scopus
  192. Y. Birnbaum, B. Long, J. Qian, J. R. Perez-Polo, and Y. Ye, “Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner,” Basic Research in Cardiology, vol. 106, no. 3, pp. 431–446, 2011. View at Publisher · View at Google Scholar · View at Scopus
  193. S. Yasuda, H. Kobayashi, M. Iwasa et al., “Antidiabetic drug pioglitazone protects the heart via activation of PPAR-γ receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 296, no. 5, pp. H1558–H1565, 2009. View at Publisher · View at Google Scholar · View at Scopus
  194. M. Collin, N. S. A. Patel, L. Dugo, and C. Thiemermann, “Role of peroxisome proliferator-activated receptor-γ in the protection afforded by 15-deoxyΔ12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin,” Critical Care Medicine, vol. 32, no. 3, pp. 826–831, 2004. View at Publisher · View at Google Scholar · View at Scopus
  195. W.-T. Wu, C.-C. Lee, C.-J. Lee, Y.-M. Subeq, R.-P. Lee, and B.-G. Hsu, “Rosiglitazone ameliorates endotoxin-induced organ damage in conscious rats,” Biological Research for Nursing, vol. 13, no. 1, pp. 38–43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  196. B. M. Jucker, C. P. Doe, C. G. Schnackenberg et al., “PPARδ activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure,” Journal of Cardiovascular Pharmacology, vol. 50, no. 1, pp. 25–34, 2007. View at Publisher · View at Google Scholar · View at Scopus
  197. C. Zizola, P. J. Kennel, H. Akashi et al., “Activation of PPARδ signaling improves skeletal muscle oxidative metabolism and endurance function in an animal model of ischemic left ventricular dysfunction,” American Journal of Physiology–Heart and Circulatory Physiology, vol. 308, no. 9, pp. H1078–H1085, 2015. View at Publisher · View at Google Scholar
  198. A. Kapoor, M. Collino, S. Castiglia, R. Fantozzi, and C. Thiemermann, “Activation of peroxisome proliferator-activated receptor-beta/delta attenuates myocardial ischemia/reperfusion injury in the rat,” Shock, vol. 34, no. 2, pp. 117–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  199. A. Kapoor, Y. Shintani, M. Collino et al., “Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 12, pp. 1506–1515, 2010. View at Publisher · View at Google Scholar · View at Scopus
  200. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.-C. Fruchart, “Mechanism of action of fibrates on lipid and lipoprotein metabolism,” Circulation, vol. 98, no. 19, pp. 2088–2093, 1998. View at Publisher · View at Google Scholar · View at Scopus
  201. M. H. Davidson, A. Armani, J. M. McKenney, and T. A. Jacobson, “Safety considerations with fibrate therapy,” The American Journal of Cardiology, vol. 99, no. 6, supplement 1, pp. S3–S18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  202. M. Jun, C. Foote, J. Lv et al., “Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis,” The Lancet, vol. 375, no. 9729, pp. 1875–1884, 2010. View at Publisher · View at Google Scholar · View at Scopus
  203. The ACCORD Study Group, H. N. Ginsberg, M. B. Elam et al., “Effects of combination lipid therapy in type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 362, pp. 1563–1574, 2010. View at Google Scholar
  204. H. B. Rubins, S. J. Robins, D. Collins et al., “Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group,” The New England Journal of Medicine, vol. 341, no. 6, pp. 410–418, 1999. View at Publisher · View at Google Scholar · View at Scopus
  205. H. Hauner, “The mode of action of thiazolidinediones,” Diabetes/Metabolism Research and Reviews, vol. 18, supplement 2, pp. S10–S15, 2002. View at Publisher · View at Google Scholar · View at Scopus
  206. J. Tonelli, W. Li, P. Kishore et al., “Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes,” Diabetes, vol. 53, no. 6, pp. 1621–1629, 2004. View at Publisher · View at Google Scholar · View at Scopus
  207. J. G. Yu, S. Javorschi, A. L. Hevener et al., “The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects,” Diabetes, vol. 51, no. 10, pp. 2968–2974, 2002. View at Publisher · View at Google Scholar · View at Scopus
  208. J. D. Lewis, L. A. Habel, C. P. Quesenberry et al., “Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes,” The Journal of the American Medical Association, vol. 314, no. 3, pp. 265–277, 2015. View at Publisher · View at Google Scholar
  209. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” The New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at Publisher · View at Google Scholar · View at Scopus
  210. S. Kaul, A. F. Bolger, D. Herrington, R. P. Giugliano, and R. H. Eckel, “Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American heart association and American college of cardiology foundation,” Circulation, vol. 121, no. 16, pp. 1868–1877, 2010. View at Publisher · View at Google Scholar · View at Scopus
  211. T. E. Delea, J. S. Edelsberg, M. Hagiwara, G. Oster, and L. S. Phillips, “Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study,” Diabetes Care, vol. 26, no. 11, pp. 2983–2989, 2003. View at Publisher · View at Google Scholar · View at Scopus
  212. D. J. Graham, R. Ouellet-Hellstrom, T. E. Macurdy et al., “Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone,” The Journal of the American Medical Association, vol. 304, no. 4, pp. 411–418, 2010. View at Publisher · View at Google Scholar · View at Scopus
  213. R. W. Nesto, D. Bell, R. O. Bonow et al., “Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the american heart association and american diabetes association,” Circulation, vol. 108, no. 23, pp. 2941–2948, 2003. View at Publisher · View at Google Scholar · View at Scopus
  214. E. Erdmann, B. Charbonnel, R. G. Wilcox et al., “Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive Study (PROactive 08),” Diabetes Care, vol. 30, no. 11, pp. 2773–2778, 2007. View at Publisher · View at Google Scholar · View at Scopus
  215. A. M. Lincoff, K. Wolski, S. J. Nicholls, and S. E. Nissen, “Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials,” The Journal of the American Medical Association, vol. 298, no. 10, pp. 1180–1188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  216. P. D. Home, S. J. Pocock, H. Beck-Nielsen et al., “Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial,” The Lancet, vol. 373, no. 9681, pp. 2125–2135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  217. K. W. Mahaffey, G. Hafley, S. Dickerson et al., “Results of a reevaluation of cardiovascular outcomes in the RECORD trial,” American Heart Journal, vol. 166, no. 2, pp. 240–249.e1, 2013. View at Publisher · View at Google Scholar · View at Scopus
  218. Y. Amano, T. Yamaguchi, K. Ohno et al., “Structural basis for telmisartan-mediated partial activation of PPAR gamma,” Hypertension Research, vol. 35, no. 7, pp. 715–719, 2012. View at Publisher · View at Google Scholar · View at Scopus
  219. Boehringer Ingelheim Pharmaceuticals I. Micardis prescribing information, 2014.
  220. S. Yusuf, H.-C. Diener, R. L. Sacco et al., “Telmisartan to prevent recurrent stroke and cardiovascular events,” The New England Journal of Medicine, vol. 359, no. 12, pp. 1225–1237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  221. K. Kappert, M. Bohm, R. Schmieder et al., “Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the telmisartan randomized assessment study in ace-intolerant subjects with cardiovascular disease (transcend) and the ongoing telmisartan alone and in combination with ramipril global end point trial (ontarget),” Circulation, vol. 126, no. 8, pp. 934–941, 2012. View at Publisher · View at Google Scholar
  222. S. Yusuf, K. K. Teo, J. Pogue et al., “Telmisartan, ramipril, or both in patients at high risk for vascular events,” The New England Journal of Medicine, vol. 358, no. 15, pp. 1547–1559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  223. D. Fitchett, “Results of the ONTARGET and TRANSCEND studies: an update and discussion,” Vascular Health and Risk Management, vol. 5, pp. 21–29, 2009. View at Google Scholar · View at Scopus
  224. A. Sharma, S. Amarnath, D. S. Kushwah, and S. Ramaswamy, “Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia—a review,” Journal of Young Pharmacists, vol. 7, no. 1, pp. 2–6, 2015. View at Publisher · View at Google Scholar · View at Scopus
  225. S. Chatterjee, A. Majumder, and S. Ray, “Observational study of effects of saroglitazar on glycaemic and lipid parameters on indian patients with type 2 diabetes,” Scientific Reports, vol. 5, article 7706, 2015. View at Publisher · View at Google Scholar
  226. Z. Discovery, Lipaglyn—Product Information, Lipaglyn, 2013.
  227. A. M. Lincoff, J.-C. Tardif, G. G. Schwartz et al., “Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the alecardio randomized clinical trial,” The Journal of the American Medical Association, vol. 311, no. 15, pp. 1515–1525, 2014. View at Publisher · View at Google Scholar · View at Scopus
  228. S. E. Nissen, K. Wolski, and E. J. Topol, “Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus,” Journal of the American Medical Association, vol. 294, no. 20, pp. 2581–2586, 2005. View at Publisher · View at Google Scholar · View at Scopus